• Sevgi Kalkanli Tas, Ender Coskunpinar, Pinar Yildiz, Mesut Bayraktaroğlu, Tuba Kose, Derya Altunkanat, Duygu Kirkik, and Mustafa Tukenmez.
• University of Health Sciences Turkey, Hamidiye Faculty of Medicine, Department of Immunology, Istanbul, Turkey.
• Afr Health Sci. 2022 Dec 1; 22 (4): 374537-45.

BackgroundVarious variants of the miR-219-1 gene are one of the first genes associated with NSCLC prognosis in the literature.ObjectivesWe aimed to genotype two different variants of the miR-219-1 gene and to investigate to using of the result as a biomarker in the diagnosis and treatment of NSCLC.Materials And MethodsThe patients were chosen according to International NSCLC criteria and genomic DNA was isolated from blood (138 patients and 100 healthy individuals). Then qRT-PCR was applied to determine the rs213210 and rs421446 variants of miR-219-1 gene polymorphisms. Allele and genotype frequencies were compared using Pearson's chi-square and Fisher's exact tests test.ResultsWe found that TT genotype (p=0,381) in rs213210 compared with CC genotype (p=0,165) and CC genotype (p=0,823) in rs421446 compared with TT genotype (p=0,537) did not show a significantly increased risk of NSCLC. There is no relationship between polymorphisms in miR-219-1 and the outcome of NSCLC.ConclusionmiRNA single nucleotide polymorphisms can be used as genetic biomarkers to predict cancer susceptibility, early diagnosis, and prognosis. Our study has shown that two variants of miR-219-1 were not related to NSCLC in the Turkish population. The reason for this can be differences in ethnicity, regions, and background of population and these differences could lead to various outcomes.© 2022 Tas SK et al.

14 keywords...

hide…